Two experimental vaccines show promise in protecting against a potential trigger of multiple sclerosis (MS).
Tested only in animals so far, the vaccines block two pathways by which the Epstein-Barr virus (EBV) takes root inside the body, said senior researcher Dr. Gary Nabel, president and CEO of ModeX Therapeutics, a small biotech startup in Natick, Mass. https://wb.md/3x13qcJ
Original source can be found here.
Alerts Sign-up